Business
Seer to Showcase AI-Driven Multi-Cancer Screening Approach and Next-Generation Proteomics Capabilities at ASMS 2026
Drs. Sang-Won Lee and Jaewoo Kang to share early insights from Seer's 20,000-sample collaboration with Korea University in breakfast symposium on AI-driven multi-cancer screeningREDWOOD CITY, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the 2026 American Society for Mass Spectrometry (ASMS) Annual Conference, taking place May 31 to June 4 at the San Diego Convention
About this update from Seer, Inc.
[{"type":"image","alt":"Seer, Inc.","displaySize":"","headline":null,"caption":"Seer, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":95,"url":"https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KAzr34r.34V3qwddJvNZmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMw--/https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b","width":300,"height":95},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/KAzr34r.34V3qwddJvNZmA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEzMw--/https://media.zenfs.com/en/globenewswire.com/54cda3f3cc4c5a0012780bcda6451a0b","width":300,"height":95}},"lazy":false},{"type":"text","content":"Drs. Sang-Won Lee and Jaewoo Kang to share early insights from Seer's 20,000-sample collaboration with Korea University in breakfast symposium on AI-driven multi-cancer screening","length":182,"tagName":"p"},{"type":"text","content":"REDWOOD CITY, Calif., May 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the 2026 American Society for Mass Spectrometry (ASMS) Annual Conference, taking place May 31 to June 4 at the San Diego Convention Center. At the meeting, Seer and a broad set of collaborators will demonstrate how the Proteograph® Product Suite is enabling deep, unbiased, scalable proteomics with peptide-level precision, empowering researchers to uncover hidden biological insights and drive new discovery across translational and population-scale research.","length":650,"tagName":"p"},{"type":"text","content":"Seer's presence at ASMS 2026 will span a featured breakfast symposium previewing one of the most ambitious applications of AI-driven proteomics to date, an oral presentation introducing next-generation proteomic data processing tools, and a diverse set of customer-led scientific presentations. Together, these sessions reflect the accelerating adoption of nanoparticle-enabled proteomics across translational research, systems biology, biomarker discovery, and precision medicine.","length":485,"tagName":"p"},{"type":"text","content":"“ASMS has long been a defining venue for the proteomics community, and the breadth of Seer-enabled science being presented this year reflects how rapidly deep,...